• Recommended brexucabtagene autoleucel (Tecartus) for two cancer patient groups through an outcome-based risk-sharing agreement.

• Continued its recommendation for burosumab (Crysvita) in children and adolescents with XLH, while expanding the eligible population.

• Added tezepelumab, depemokimab and omalizumab to the treatment guidance for severe chronic rhinosinusitis with nasal polyps. Their use awaits an Amgros tender and new offered prices.

• Decided on a clock-stop for mepolizumab for uncontrolled COPD while considering a conditional agreement.

• Kept two assessments of trastuzumab deruxtecan (Enhertu) in clock-stop pending further discussions on an outcome-based agreement.

• Did not recommend brentuximab vedotin (Adcetris) for Hodgkin lymphoma, citing unacceptable costs relative to documented effect and uncertainty about long-term adverse effects.

The Council also updated guidance for metastatic renal cancer and approved a protocol for forthcoming guidance on anaemia in chronic kidney disease.

Read more at https://medicinraadet.dk/nyheder/2026/overblik-beslutninger-pa-radsmodet-den-30-september-2026

Indlægget Innovative agreements are gaining further traction in Denmark blev først udgivet på NHTA.

Recommended

• Vorasidenib (Voranigo) for patients with a rare, incurable type of brain cancer after surgery.

• Mavacamten (Camzyos) for patients with obstructive hypertrophic cardiomyopathy when a cardiac procedure is not an option.

Clock-stop

• Trastuzumab deruxtecan (Enhertu) for cancer in the gastroesophageal junction and stomach, with discussion of whether the company wants to pursue an alternative price agreement.

• Brentuximab vedotin (Adcetris) for adults with Hodgkin lymphoma, pending a better basis for comparison with standard treatment, especially on long-term side effects.

Not recommended

• Pegcetacoplan (Aspaveli) for rare chronic kidney disease.

• Maralixibat (Livmarli) for itching in Alagille syndrome.

The council also updated the first-line multiple myeloma recommendation, stating BorLenDex should remain first choice for at least 60% of patients.

From December 2026, assessment reports will include a new section on patients’ perspectives.

Read more at https://medicinraadet.dk/nyheder/2026/overblik-beslutninger-pa-radsmodet-den-2-september-2026

Indlægget Medicinrådet issues two green lights and two red lights blev først udgivet på NHTA.

The portal will provide pharmaceutical companies a single place to:

• submit requests for assessment of new medicines

• track status, activities, and milestones

• communicate with The Danish Medicines Council more securely

According to Danish Medicines Council, the first phase covers requests for assessments only. In early 2027, the portal will also accept full applications, including larger files that have been difficult to send by email.

The system was developed in dialogue with representatives from nine pharmaceutical companies, who tested the portal and provided feedback on functions, workflows, and user experience.

The Danish Medicines Council says the portal is part of its broader work to digitalise and streamline assessments of new medicines.

Read more at https://medicinraadet.dk/nyheder/2026/ny-portal-gor-det-lettere-for-virksomheder-at-ansoge-medicinradet

Indlægget The Danish Medicines Council launches new company application portal blev først udgivet på NHTA.

What is new

• A new overview and algorithm give primary care a quick view of recommended pharmacological treatment for type 2 diabetes.

• The material brings together Medicinrådet’s treatment recommendations from the May 2026 guidance.

• It includes information on efficacy, prices, side effects and other relevant details.

• Prices will be updated if they change significantly, for example due to patent expiry or supply issues.

• The overview replaces the previous medicine recommendation in this area and will also be part of the national basis list expected in autumn 2026.

Aim
The stated aim is to give doctors and other health professionals a practical tool that can be used directly in a busy clinical setting.

Read more at https://medicinraadet.dk/nyheder/2026/nyt-overblik-over-laegemidler-til-type-2-diabetes

Indlægget New overview simplifies type 2 diabetes treatment guidance in Denmark blev først udgivet på NHTA.

Key points

• Six new medicines were recommended.

• Three medicines were directly placed in treatment guidelines.

• Four medicines were not recommended as standard treatment.

Recommended as standard treatment

• Durvalumab was recommended for resectable gastric cancer in combination with FLOT.

• Obinutuzumab was recommended for adults with lupus nephritis for up to one year.

• Bulevirtid was recommended for chronic hepatitis D with severe liver damage.

• Cilta-cel was extended to patients previously treated with other BCMA-targeted medicines.

• Glofitamab, olaparib, and sotatercept all received conditional recommendations.

Direct placements into treatment guidelines

• Depemokimab is included directly in the treatment guideline for biological medicines for severe asthma.

• Leuprorelin is included directly in the evidence review of medicines for medical castration in prostate cancer.

• Somapacitan is included directly in the evidence review of medicines for growth hormone deficiency.

Not recommended as standard treatment

• Natriumthiosulfat, givinostat, cabozantinib, and tafasitamab.

Process updates

• Two ongoing assessments were put on hold.

• Guidance for metastatic castration-sensitive prostate cancer and first-line unresectable NSCLC was updated after new tenders and prices.

Read more at https://medicinraadet.dk/nyheder/2026/overblik-medicinradets-beslutninger-i-juni-2026

Indlægget Six new medicines were recommended by the Danish Medicines Council in June blev først udgivet på NHTA.

The Danish Medicines Council has published its first national basis list with medicine recommendations for 15 common disease areas. The list replaces the five regional basis lists previously prepared by the regions.

What it includes

• First-choice medicine recommendations for adults across 15 disease areas.

• Cases where more than one medicine may be listed if products are assessed as equally efficacious and equally priced.

• A short print-friendly version and a full version with supporting text and source references.

Timing

• The list will next be updated in November 2026, including recommendations for type 2 diabetes.

• Regional basis lists on sundhed.dk will be updated soon to reflect the national recommendations.

Read more at https://medicinraadet.dk/nyheder/2026/ny-national-basisliste-til-praktiserende-laeger-fra-medicinradet

Indlægget The Danish Medicines Council launches national basis list for GPs blev først udgivet på NHTA.

Key points:

• Companies can now submit proposals up to and including the 6th week of the assessment process. Before, companies needed to submit these proposals from the beginning of the process.

• The change does not delay planned meetings with expert committees or the expected recommendation timeline.

• Alternative agreements can be used when there is uncertainty about a medicine’s effect or costs.

• The updated approach is part of the revised guidance on alternative agreements and follows cooperation with LIF.

Alternative agreements, including effect-based and economically based models, are already used in Denmark, and the DMC and Amgros encourages companies to utilise this opportunity when it is relevant.

Read more at https://medicinraadet.dk/nyheder/2026/medicinradet-og-amgros-giver-laegemiddelvirksomheder-mere-tid-til-at-foresla-alternative-prisaftaler

Indlægget The Danish Medicines Council and Amgros allow companies more time to propose alternative agreements blev først udgivet på NHTA.

The secretariat will move from four departments to three centres: Center for Chronic Diseases, Center for Cancer, and Center for Strategy and Staffing.

Why this change?:

• The change is a respond to more new tasks and a rising number of applications from pharmaceutical companies for assessment of new medicines.

• The new structure brings together staff with expertise in cancer, chronic disease, and cross-cutting tasks.

• Medicinrådet says the aim is to support its core work on medicine recommendations and guidance for general practice.

• The secretariat currently has about 90 employees.

Centre responsibilities:

• Center for Chronic Dieases covers chronic and rare diseases, ATMP medicines, treatment guidance for hospitals, and guidance for general practitioners.

• Center for Cancer covers cancer medicines, RWE initiatives, and methods development.

• Center for Strategy and Staffing covers communication, law, strategy, digitalisation, data, HR, finance, administration, and leadership support.

Read more at https://medicinraadet.dk/nyheder/2026/ny-organisering-af-medicinradets-sekretariat-fra-den-1-juni-2026

Indlægget The Danish Medicines Council reorganises its secretariat into three centres blev først udgivet på NHTA.

The treatment guidelines provide clinicians a quick overview of the council’s recommendations in a practice-oriented format, including:

• starting medication

• choice of product

• dose adjustment

• follow-up

• stopping treatment

Two guides are aimed at practicing child and adolescent psychiatrists and psychiatrists. A third guide is for general practitioners who may take over follow-up of adult patients who are stable on medication.

The guides are based on The Danish Medicines Council’s ADHD treatment evidence summary from December 2025 and are accompanied by a table with an overview of the relevant medicines and prices.

They are intended to support continuity of care across sectors.

Read more at https://medicinraadet.dk/nyheder/2026/nye-korte-vejledninger-til-psykiatere-og-praktiserende-laeger-om-adhd-medicin

Indlægget The Danish Medicines Council issues ADHD medication guidelines for the primary healthcare sector blev først udgivet på NHTA.

• Pertuzumab added to trastuzumab for adjuvant treatment of early HER2-positive breast cancer, based on new submitted data (reversing a 2018 decision); estimated impact: ~50 patients/year.

• Polihexanid for acanthamoeba keratitis (~35 patients/year); the council notes no documented better clinical effect than prior magistral products, but higher cost, and will revisit the recommendation after two years.

• Rucaparib for 1st line maintenance in advanced ovarian/fallopian tube/primary peritoneal cancer; effect described as comparable to niraparib (~100 patients/year), with a recommendation to use the cheaper option for at least 80% of patients.

• Toripalimab + cisplatin and gemcitabine for recurrent/metastatic nasopharyngeal carcinoma; estimated 10–15 eligible patients/year.

Other notes include two direct placements (donidalorsen; nusinersen 50/28 mg), multiple myeloma guideline updates, two non-recommendations (ravulizumab; vutrisiran), and a clock-stop for glofitamab.

Read more at https://medicinraadet.dk/nyheder/2026/overblik-medicinradets-beslutninger-i-april-2026

Indlægget Danish Medicines Council decisions from April 2026 blev først udgivet på NHTA.